GET THE APP

MicroRNA expression profiling to identify potential biomarkers in inflammatory breast cancer
..

Cancer Science & Therapy

ISSN: 1948-5956

Open Access

MicroRNA expression profiling to identify potential biomarkers in inflammatory breast cancer


2nd World Congress on Breast Cancer

September 19-21, 2016 Phoenix, USA

Lei Huo

The University of Texas MD Anderson Cancer Center, USA

Keynote: J Cancer Sci Ther

Abstract :

Inflammatory breast cancer is characterized by clinical hallmarks of diffuse erythema and edema (peau dâ??orange) involving one third or more of the breast skin caused by tumor emboli blocking dermal lymphatics, and rapid progression from the onset of the disease. It is the most aggressive form of breast cancer, comprising 1-5% of newly diagnosed breast cancer in the United States. The survival outcomes of patients with inflammatory breast cancer are poor with standard therapy. There is an urgent need for new therapeutic targets. At the molecular level, the few published mRNA expression profiling studies have indicated that transcriptional heterogeneity exists in inflammatory breast cancer as extensively as in non-inflammatory breast cancer. Recent advances have implicated the role of microRNA as oncogenes or tumor suppressor genes in tumorigenesis, metastasis and response to treatment in various cancer types including breast cancer. In our recent study, the microRNA expression profiles of 23 inflammatory breast cancer, 24 non-inflammatory advanced breast cancer and 12 normal breast tissue fresh frozen samples were generated using a previously validated microRNA microarray assay. Among the differentially expressed microRNAs, microRNA-205 expression was decreased not only in tumor compared with normal breast tissue, but also in inflammatory breast cancer compared with non-inflammatory breast cancer. Lower expression of microRNA-205 correlated with worse distant metastasis-free survival and overall survival in our cohort. Thus, microRNA-205 may serve as a therapeutic target in advanced breast cancer including inflammatory breast cancer.

Biography :

Lei Huo received her Bachelor of Medicine degree at Beijing Medical University and her PhD in Molecular Biology and Genetics at Northwestern University, Chicago. A practicing breast pathologist in MD Anderson Cancer Center, she is actively involved in clinical and translational research in the field of breast cancer. Her research interests include molecular and immune-histochemical markers in the diagnosis and treatment of breast cancer, among others.

Email: LeiHuo@mdanderson.org

Google Scholar citation report
Citations: 3644

Cancer Science & Therapy received 3644 citations as per Google Scholar report

Cancer Science & Therapy peer review process verified at publons

Indexed In

 
arrow_upward arrow_upward